STOCK TITAN

IMPACT Biomedical (IBO) CFO sells 45,000 shares, keeps 155,122

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

IMPACT BIOMEDICAL INC. Chief Financial Officer Todd D. Macko reported open-market sales of 45,000 shares of Common Stock. The transactions occurred on March 25 and March 27, 2026 at prices around $0.60 per share. After these sales, he directly holds 155,122 shares of Common Stock.

Positive

  • None.

Negative

  • None.

Insights

CFO executed modest open-market sales while retaining a sizable share position.

The Chief Financial Officer, Todd D. Macko, sold a total of 45,000 shares of IMPACT BIOMEDICAL INC. Common Stock in two open-market transactions, at prices near $0.60 per share. These are straightforward non-derivative stock sales.

Following the transactions, he continues to hold 155,122 shares directly, indicating he retains a meaningful equity stake. The filing does not reference options, derivatives, or a trading plan, and shows no remaining derivative positions, so this appears to be a routine share sale rather than a complex exercise-and-sell event.

Insider Macko Todd D
Role Chief Financial Officer
Sold 45,000 shs ($25K)
Type Security Shares Price Value
Sale Common Stock 43,400 $0.5615 $24K
Sale Common Stock 1,600 $0.6008 $961.28
Holdings After Transaction: Common Stock — 155,122 shares (Direct)
Footnotes (1)
Total shares sold 45,000 shares Net open-market sales in March 2026
March 27, 2026 sale size 43,400 shares Open-market sale of Common Stock
March 27, 2026 sale price $0.5615 per share Reported transaction price for Common Stock
March 25, 2026 sale size 1,600 shares Open-market sale of Common Stock
March 25, 2026 sale price $0.6008 per share Reported transaction price for Common Stock
Shares held after transactions 155,122 shares Direct Common Stock ownership after March 27, 2026
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
""security_title": "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
non-derivative financial
""transaction_type": "non-derivative""
transaction code "S" financial
""transaction_code": "S""
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Macko Todd D

(Last)(First)(Middle)
6891 DORSETT TRAIL

(Street)
VICTOR NEW YORK 14564

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
IMPACT BIOMEDICAL INC. [ IBO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/25/2026S1,600D$0.6008198,122D
Common Stock03/27/2026S43,400D$0.5615155,122D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
/s/ Todd Macko03/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transactions did IMPACT BIOMEDICAL INC. (IBO) report for its CFO?

The filing shows CFO Todd D. Macko completed two open-market sales totaling 45,000 shares of IMPACT BIOMEDICAL INC. Common Stock. These sales occurred on March 25 and March 27, 2026, and are reported as non-derivative stock transactions under Section 16 rules.

At what prices did the IMPACT BIOMEDICAL INC. (IBO) CFO sell his shares?

Todd D. Macko sold 1,600 shares at an average price of about $0.6008 per share and 43,400 shares at about $0.5615 per share. Both transactions involved Common Stock and are characterized as open-market or private sales in the official filing.

How many IMPACT BIOMEDICAL INC. (IBO) shares does the CFO hold after these sales?

After the reported sales, CFO Todd D. Macko directly holds 155,122 shares of IMPACT BIOMEDICAL INC. Common Stock. This post-transaction ownership figure comes from the Form 4 and reflects his remaining direct equity stake following the two open-market sales disclosed.

How many IMPACT BIOMEDICAL INC. (IBO) shares did the CFO sell in total?

The Form 4 shows that CFO Todd D. Macko sold a combined 45,000 shares of Common Stock. He sold 1,600 shares on March 25, 2026, and 43,400 shares on March 27, 2026, all reported as open-market or private transactions under code “S.”

Were any derivatives or stock options involved in the IMPACT BIOMEDICAL INC. (IBO) CFO’s transactions?

The reported transactions involve only non-derivative Common Stock sales. The derivative section in the filing is empty, and there is no disclosure of option exercises, conversions, or other derivative activity associated with these March 2026 transactions by CFO Todd D. Macko.